Ocumetics Technology

Ocumetics Technology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Ocumetics Technology (OTC.V) as of Nov 5, 2026 is 64.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 83.22 % — a change of -21.91% (lower).

FCF Conversion

64.98 %

YoY

-21.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Ocumetics Technology is 2025 64.98 % . FCF Conversion Rate (FCF/EBITDA) of Ocumetics Technology was 2024 83.22 % . It decreases by -21.91% lower compared to the previous year.

The Ocumetics Technology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
0.47 CAD
Jan 1, 2021
35.71 CAD
Jan 1, 2022
75.92 CAD
Jan 1, 2023
60.06 CAD
Jan 1, 2024
83.22 CAD
Jan 1, 2025
64.98 CAD
The Ocumetics Technology FCF Conversion history
YEARFCF ConversionYoY
64.98 %-21.91%
83.22 %+38.55%
60.06 %-20.89%
75.92 %+112.59%
35.71 %+7,439.60%
0.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ocumetics Technology Stock analysis

What does Ocumetics Technology do? Ocumetics Technology Corp develops the Bionic Lens, an expandable intraocular lens designed for people over 45 to eliminate corrective lenses. The company focuses on adaptive lens designs for intraocular lenses that allow natural eye muscle activity to shift focus between distance and near vision. The Bionic Lens uses self-adapting suspension systems with cushions conforming to each recipient’s eye parameters, compressing the optical interface during relaxation of ciliary muscles for distant focus. The firm is in preclinical study stage for ophthalmic industry technology. Ocumetics Technology Corp specializes in intraocular lens development targeting the ophthalmic industry segment. The Bionic Lens is the company’s primary product, designed to fit within the natural lens compartment of the eye without requiring corrective lenses. The company’s technology aims to address the needs of individuals over 45 years of age who seek alternatives to traditional corrective lenses. The preclinical study stage indicates the company is developing its product for future market entry in the ophthalmic sector. The Bionic Lens features a unique suspension system that modulates curvature change through self-adapting cushions. These cushions conform to individual eye parameters, enabling the lens to shift focus naturally with ciliary muscle activity. The product’s design eliminates the need for corrective lenses by leveraging the eye’s natural mechanisms for focusing on distant objects during muscle relaxation. Ocumetics Technology Corp is positioned to serve the aging population seeking vision correction solutions without traditional eyewear. Ocumetics Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ocumetics Technology stock

FCF Conversion Rate (FCF/EBITDA) of Ocumetics Technology is 64.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Ocumetics Technology changed from 83.22 % to 64.98 %, representing a -21.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Ocumetics Technology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Ocumetics Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ocumetics Technology

All Key Metrics — Ocumetics Technology